Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
  • C12N5/0662—Stem cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
  • C12N5/0662—Stem cells
  • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/475—Growth factors; Growth regulators
  • C07K14/515—Angiogenesic factors; Angiogenin
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
  • C12N9/18—Carboxylic ester hydrolases (3.1.1)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y301/00—Hydrolases acting on ester bonds (3.1)
  • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
  • C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2510/00—Genetically modified cells

Definitions

• the present disclosure generally relates to the treatment of inflammatory diseases such as systemic inflammatory response syndrome (SIRS), multiple organ dysfunction symptom (MODS), septic shock and sepsis.
• SIRS systemic inflammatory response syndrome
• MODS multiple organ dysfunction symptom
• septic shock septic shock and sepsis.
• SIRS Systemic inflammatory response syndrome
• LPS Lipopolysaccharide
• the present disclosure provides the following items 1 to 42:
• a mesenchymal stem cell that is genetically modified to overexpress an acyloxyacyl hydrolase (AOAH) polypeptide.
• the MSC of item 2, wherein the recombinant AOAH polypeptide comprises an amino acid sequence that is at least 70% identical to the amino acid sequence of residues 35 to 575 of SEQ ID NO: 5.
• the MSC of item 4, wherein the recombinant AOAH polypeptide comprises the amino acid sequence of residues 35 to 575 of SEQ ID NO: 5.
• MSC any one of items 2 to 6, wherein the MSC comprises a first exogenous nucleic acid comprising an AOAH polypeptide-encoding region operably linked to a promoter or promoter/enhancer combination.
• MSC cytomegalovirus
• EF1 elongation factor- 1
• the AOAH polypeptide-encoding region comprises a nucleotide sequence having at least 70% identity with nucleotides 7 to 1734 of SEQ ID NO: 1 .
• the MSC of item 10 wherein the AOAH polypeptide-encoding region comprises a nucleotide sequence having at least 90% identity with nucleotides 7 to 1734 of SEQ ID NO: 1 .
• the MSC of item 1 1 wherein the AOAH polypeptide-encoding region comprises the nucleotide sequence of nucleotides 7 to 1734 of SEQ ID NO:1 .
• ANGPT1 angiopoeitin-1
• the MSC of item 13 wherein the MSC expresses a recombinant ANGPT 1 polypeptide.
• the recombinant ANGPT1 polypeptide comprises an amino acid sequence that is at least 70% identical to the amino acid sequence of residues 16 to 498 of SEQ ID NO: 7.
• ANGPT1 polypeptide comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of residues 16 to 498 of SEQ ID NO: 7.
• MSC any one of items 13 to 17, wherein the MSC comprises a second exogenous nucleic acid comprising an ANGPT1 polypeptide-encoding region operably linked to a second promoter or promoter/enhancer combination.
• ANGPT1 polypeptide-encoding region comprises a nucleotide sequence having at least 70% identity with nucleotides 7 to 1503 of SEQ ID NO:3.
• ANGPT 1 polypeptide-encoding region comprises a nucleotide sequence having at least 90% identity with nucleotides 7 to 1503 of SEQ ID NO:3.
• the MSC of item 22, wherein the AOAH polypeptide-encoding region comprises the nucleotide sequence of nucleotides 7 to 1503 of SEQ ID NO:3.
• SIRS systemic inflammatory response syndrome
• the MSC for use according to any one of items 27 to 29, wherein the MSC are allogenic with respect to the subject.
• the MSC for use according to any one of items 27 to 29, wherein the MSC are autologous with respect to the subject.
• SIRS systemic inflammatory response syndrome
• FIG. 1A depicts the construction of the plasmid (#2) comprising the AOAH coding sequence under the control of an EF-1 promoter.
• FIG. 1 B depicts the construction of the plasmid (#3) comprising the AOAH coding sequence under the control of a CMV promoter.
• FIG. 1 C depicts the construction of the plasmid (#1 ) comprising the AOAH coding sequence under the control of a CMV promoter and a CMV enhancer.
• FIG. 2 is a graph showing the expression of AOAH by MSC transfected with plasmid #1 (black bar) (ii) plasmid #2 (dark grey bar) and (iii) plasmid #3 (light grey bar). Expression was measured by Western Blot on cell lysates and the expression was normalized based on beta- actin expression.
• FIGs. 3A and 3B are graphs showing the total internal AOAH expression (FIG. 3A) and the proportion of mature AOAH relative to total AOAH expression (FIG. 3B) in MSC transfected with the plasmid #1 and harvested 24h, 48h and 72h post-transfection. Expression was measured by Western Blot on cell lysates and the expression was normalized based on beta- actin expression.
• FIG. 3C is a graph showing the levels of AOAH in the culture medium of MSC transfected with the plasmid #1 and harvested 24h, 48h and 72h post-transfection. Expression was measured by ELISA.
• FIG. 4A is a schematic of the endotoxin-induced sepsis animal model used in the present studies. Endotoxemia was induced in mice by intraperitoneal injection of LPS, and the mice were treated with AOAH-transfected MSC (NT002), untransfected MSC or vehicle 1 h post- LPS injection. At 20h post-LPS injection, plasma from mice was harvested to determine the plasmatic levels of pro-inflammatory cytokines or chemokines.
• * P ⁇ 0.05; ** P ⁇ 0.01 One-way ANOVA test).
• FIG. 5A is a schematic of the E. coli- induced sepsis animal model used in the present studies.
• E. coli was induced in mice by intraperitoneal injection, and the mice were treated with NT002 (or vehicle) 1 h post-bacteria injection. Animal wellness was assessed for 5 days to determine the survival rate.
• FIG. 5B shows the survival rate of mice infected with E. coli and treated with NT002 or vehicle. Sham mice (no sepsis) received vehicle treatment as control. * P ⁇ 0.05 (Log-rank test).
• FIG. 6A depicts the construction of plasmid #4 comprising the AOAH coding sequence and ANGPT1 coding sequence.
• FIG. 6B shows the codon-optimized sequence of the nucleic acid encoding human AOAH used in the studies described herein (SEQ ID NO: 1).
• the coding sequence is in bold, the first 6 nucleotides represent the Kozak sequence and the last three nucleotides correspond to the stop codon.
• FIG. 6C shows the sequence of the nucleic acid encoding human ANGPT 1 used in the studies described herein (SEQ ID NO: 3).
• the coding sequence is in bold, the first 6 nucleotides represent the Kozak sequence and the last three nucleotides correspond to the stop codon.
• FIG. 6D shows the survival rate of mice infected with E. coli and treated with NT003 (AOAH/ANGPT1 -transfected MSC) or vehicle.
• FIG. 7A is a schematic of the cecal ligation and puncture (CLP)-induced sepsis animal model used in the present studies. Once sepsis was induced, the mice were treated with NT003 (AOAH/ANGPT1 -transfected MSCs) or vehicle 6h post-CLP. Sham mice (no sepsis) received vehicle treatment as control. Animal wellness was assessed for 5 days to determine the survival rate.
• FIG. 7B shows the combined survival data of CLP mice treated with NT003, or vehicle.
• FIG. 8A shows the amino acid sequence of human AOAH (isoform 1 , UniProtKB accession number P28039, SEQ ID NO:5), with the signal peptide sequence underlined (residues 1 -23), the propeptide sequence (residues 24-34) in italics and the sequence of the mature form (residues 35-575) in bold.
• FIG. 8B shows the nucleotide sequence of the cDNA encoding human AOAH (isoform 1 , NCBI Reference Sequence: NM_001637.3, SEQ ID NO:6), with the coding sequence in bold.
• FIG. 9A shows the amino acid sequence of human ANGPT1 (isoform 1 , UniProtKB accession number Q15389-1 , SEQ ID NO:7), with the signal peptide sequence underlined (residues 1 -15) and the sequence of the mature form (residues 16-498) in bold.
• FIGs. 9B and 9C show the nucleotide sequence of the cDNA encoding human ANGPT1 (isoform 1 , NCBI Reference Sequence: NM_001 146.4, SEQ ID NO:8), with the coding sequence in bold.
• the term “about” has its ordinary meaning.
• the term“about” is used to indicate that a value includes an inherent variation of error for the device or the method being employed to determine the value, or encompass values close to the recited values, for example within 10% of the recited values (or range of values).
• MSCs mesenchymal stem cells
• AOAH acyloxyacyl hydrolase
• ANGPT1 angiopoeitin-1
• the present disclosure relates to a mesenchymal stem cell (MSC) that is genetically modified to overexpress an acyloxyacyl hydrolase (AOAH) polypeptide.
• MSC mesenchymal stem cell
• AOAH acyloxyacyl hydrolase
• Acyloxyacyl hydrolase (AOAH, EC 3.1 .1 .77) is a protein of 575 amino acids in human (UniProtKB accession number P28039, FIG. 8A, SEQ ID NO:5) that includes an amino-terminal signal peptide of 23 amino acids as well as a propeptide of 1 1 amino acids (residues 24-34). It comprises two disulfide-linked subunits: a small subunit encompassing residues 35-156 and a large subunit encompassing residues 157-575.
• AOAH is mainly produced by monocyte- macrophages, neutrophils, dendritic cells, and renal cortical epithelial cells, and selectively removes the secondary (acyloxyacyl-linked) fatty acyl from lipid A present in Gram-negative bacterial lipopolysaccharides (LPS). Its active site is the serine at position 263 located in the Gly-Asp-Ser-(Leu) [GDS(L)] motif. Mutations of residues 61 , 173, 345 and 379 have been shown to have no effect on enzymatic activity, whereas enzymatic activity is decreased or lost by mutations at residues 263, 372 and 419.
• the MSC is further genetically modified to overexpress a second polypeptide, preferably a polypeptide that may be useful for the treatment of SIRS/sepsis.
• the second polypeptide is an angiopoetin-1 (ANGPT1 ) polypeptide.
• Angiopoietin-1 is a protein of 498 amino acids in human (UniProtKB accession number Q15389, FIG. 9A, SEQ ID NO:7) that includes an amino-terminal signal peptide of 15 amino acids. It comprises a super clustering domain encompassing residues 81 - 1 19 and a central coiled domain encompassing residues 153-261 that are involved in ANGPT1 oligomerization, and a Fibrinogen C-terminal domain encompassing residues 277-497 that is involved in the binding to its target receptor.
• This secreted glycoprotein binds and activates the TEK/TIE2 receptor tyrosine kinase (CD202B), expressed almost exclusively in endothelial cells, by inducing its dimerization and tyrosine phosphorylation.
• Mutation of position 1 19 (A1 19S) has been shown to reduce binding capability to its receptor.
• Mutation of position 249 (K249R) has been detected in subjects with primary congenital glaucoma (PCG) (associated with a defect in ANGPT/TEK signaling) and is believed to reduce its biological activity. Deletion of the five C- terminal amino acids (R494*) is predicted to destabilize the protein (Thomson et al., J Clin Invest. 2017 Dec 1 ; 127(12): 4421 -4436).
• overexpress means that the level of expression of AOAH and/or of the second polypeptide (e.g., ANGPT1 ) in the genetically-modified MSC is higher than the level of expression of AOAH and/or of the second polypeptide (e.g., ANGPT1 ) in a corresponding MSC that does not comprise the genetic modification(s).
• the level of expression of AOAH and/or of the second polypeptide (e.g., ANGPT1) in the genetically-modified MSC is at least 20%, 50%, 100% (2-fold), 200% (3-fold), 300% (4-fold), 400% (5-fold), 900% (10-fold), 20-fold, 50-fold or 100-fold higher than the level of expression of AOAH and/or of the second polypeptide (e.g., ANGPT1) in a corresponding MSC that does not comprise the genetic modification.
• the overexpression of the AOAH protein and/or of the second polypeptide is achieved by increasing the expression of the endogenous AOAH gene and/or of the gene encoding the second polypeptide (e.g., ANGPT1) in the MSC.
• This may be achieved, for example, by introducing suitable promoter(s) and/or transcriptional regulatory (e.g., enhancer) sequences in transcriptional relationship with (i.e. operably-linked to) the endogenous AOAH gene and/or of the gene encoding the second polypeptide (e.g., ANGPT1 ).
• this may be achieved by excising/inactivating a transcriptional repressor sequence that inhibits the expression of the endogenous AOAH gene and/or of the gene encoding the second polypeptide (e.g., ANGPT1 ).
• a transcriptional repressor sequence that inhibits the expression of the endogenous AOAH gene and/or of the gene encoding the second polypeptide (e.g., ANGPT1 ).
• Introduction of promoter(s) and/or transcriptional regulatory (e.g., enhancer) sequences and excision/inactivation of transcriptional repressor sequences to induce overexpression of endogenous AOAH gene in the MSC may be achieved using genome editing techniques. Genome editing techniques can modify gene expression in a target cell by inserting, replacing, or removing DNA in the genome using an artificially engineered nuclease.
• nucleases may include zinc finger nucleases (ZPNs) (Gommans et a!., J. Mol Biol, 354(3): 507-519 (2005)), transcription activator-like effector nucleases (TALENs) (Zhang et al., Nature Biotechnol, 29: 149-153 (201 1 )), the CRISPR/Cas system (Cheng et al., Cell Res., 23: 1 163-71 ] (2013)), and engineered meganucleases (Riviere et al., Gene Ther., 21 (5): 529-32 (2014)).
• ZPNs zinc finger nucleases
• TALENs transcription activator-like effector nucleases
• CRISPR/Cas system Choeng et al., Cell Res., 23: 1 163-71 ] (2013)
• engineered meganucleases Rude et al., Gene Ther., 21 (5): 529-32 (2014).
• the nucleases create specific double-stranded breaks (DSBs) at targeted locations in the genome, and use endogenous mechanisms in the cell to repair the induced break by homologous recombination (HR) and nonhomologous end-joining (NHEJ).
• HR homologous recombination
• NHEJ nonhomologous end-joining
• Such techniques may be used to achieve overexpression of endogenous AOAH and/or of the endogenous gene encoding the second polypeptide (e.g., ANGPT1 ) in the MSCs.
• a first nucleic acid sequence is“operably-linked” with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
• a promoter is operably-linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
• operably- linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in reading frame.
• enhancers generally function when separated from the promoters by several kilobases and intronic sequences may be of variable lengths, some nucleic acids may be operably-linked but not contiguous.
• Transcriptional regulatory sequences or “transcriptional regulatory elements” are generic terms that refer to DNA sequences, such as initiation and termination signals, enhancers, and promoters, splicing signals, polyadenylation signals, etc., which induce or control transcription of protein coding sequences with which they are operably-linked.
• the overexpression of the AOAH protein and/or of the second polypeptide is achieved by inducing the expression of a recombinant (i.e. exogenous) AOAH polypeptide and/or of a recombinant second polypeptide (e.g., ANGPT1 ) in the MSC.
• a recombinant i.e. exogenous
• a recombinant second polypeptide e.g., ANGPT1
• the present disclosure relates to a genetically-modified MSC comprising or overexpressing a recombinant (i.e. exogenous) AOAH polypeptide.
• the genetically-modified MSC further comprises or overexpresses a recombinant (i.e. exogenous) second polypeptide, preferably ANGPT1 .
• recombinant means that something has been recombined, so that when made in reference to a nucleic acid, the term refers to a molecule that is comprised of nucleic acid sequences that are joined together or produced by means of molecular biological techniques.
• the term“recombinant” when made in reference to a protein or a polypeptide refers to a protein or polypeptide molecule that is not synthesized from the native genome of the cell, e.g., which is expressed from a recombinant nucleic acid construct created by means of molecular biological techniques (whether or not this synthetic nucleic acid construct is integrated in the genome of the cell).
• Recombinant nucleic acid constructs may include a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature. Referring to a nucleic acid construct as“recombinant” therefore indicates that the nucleic acid molecule has been manipulated using genetic engineering, i.e. by human intervention. Recombinant nucleic acid constructs may for example be introduced into a host cell by transformation (e.g., transduction or transfection).
• Such recombinant nucleic acid constructs may include sequences derived from the same host cell species or from different host cell species, which have been isolated and reintroduced into cells of the host species. Recombinant nucleic acid construct sequences may become integrated into a host cell genome, either as a result of the original transformation of the host cells, or as the result of subsequent recombination and/or repair events.
• the recombinant (i.e. exogenous) AOAH polypeptide comprises or consists of a sequence that is at least 50, 60 or 70% identical to the amino acid sequence of mature native human AOAH depicted in FIG. 8A/SEQ ID NO:5 (residues 35-575) and that exhibits the enzymatic activity of native human AOAH.
• the recombinant (i.e. exogenous) AOAH polypeptide comprises or consists of a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of mature native human AOAH depicted in FIG.
• the recombinant (i.e. exogenous) AOAH polypeptide comprises or consists of a sequence that is at least 50, 60 or 70% identical to the amino acid sequence of native human AOAH precursor depicted in FIG. 8A/SEQ ID NO:5 (residues 24-575) and that exhibits the enzymatic activity of native human AOAH.
• the recombinant (i.e. exogenous) AOAH polypeptide comprises or consists of a sequence that is at least 50, 60 or 70% identical to the amino acid sequence of native human AOAH precursor depicted in FIG. 8A/SEQ ID NO:5 (residues 24-575) and that exhibits the enzymatic activity of native human AOAH.
• the recombinant i.e.
• exogenous AOAH polypeptide comprises or consists of a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of native human AOAH precursor depicted in FIG. 8A/SEQ ID NO:5 (residues 24-575) and that exhibits the enzymatic activity of native human AOAH.
• the recombinant (i.e. exogenous) AOAH polypeptide comprises or consists of a sequence that is at least 50, 60 or 70% identical to the amino acid sequence of full-length native human AOAH depicted in FIG.
• the recombinant (i.e. exogenous) AOAH polypeptide comprises or consists of a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of full-length native human AOAH depicted in FIG. 8A/SEQ ID NO:5 (residues 1 -575) and that exhibits the enzymatic activity of native human AOAH.
• the recombinant (i.e. exogenous) AOAH polypeptide may be the native human AOAH protein (full-length, precursor or mature form) or an enzymatically active variant thereof comprising amino acid deletions, substitutions and/or additions that do not significantly interfere with the enzymatic activity.
• the variant exhibits an enzymatic activity that is at least 70%, 75%, 80%, 85%, 90%, 95% or 100% that of native human AOAH.
• the variant does not comprise a mutation in the Gly-Asp-Ser-(Leu) [GDS(L)] motif.
• the variant does not comprise a mutation at a position corresponding to residues 263, 372 or 419 of full-length native human AOAH.
• the variant comprises one or more conservative substitutions.
• Conservative amino acid substitutions are known in the art, and include amino acid substitutions in which one amino acid having certain physical and or chemical properties is exchanged for another amino acid that has the same chemical or physical properties.
• the conservative amino acid substitution can be an acidic amino acid substituted for another acidic amino acid (e.g., Asp to Glu or vice-versa), an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, lie, Leu, Met, Phe, Pro, Trp, Val, etc), a basic amino acid substituted for another basic amino acid (Lys, Arg, etc.), an amino acid with a polar side chain substituted for another amino acid with a polar side chain (Asn, Cys, Gin, Ser, Thr. Tyr, etc.).
• an amino acid with a polar side chain substituted for another amino acid with a nonpolar side chain e.g., Ala, Gly, Val, lie, Leu, Met, Phe, Pro, Trp, Val, etc
• a basic amino acid substituted for another basic amino acid e.g., Ala, Gly, Val, lie, Leu, Met, Phe,
• the variants can comprise the amino acid sequence of the native AOAH protein or polypeptide with at least one non-conservative amino acid substitution.
• the non-conservative amino acid substitution enhances the enzymatic activity of the variant, such that the enzymatic activity of the variant is increased relative to the native AOAH protein or polypeptide.
• the MSC is transformed by a recombinant nucleic acid encoding the recombinant (i.e. exogenous) AOAH polypeptide.
• the present disclosure relates to a genetically-modified MSC comprising a recombinant (i.e. exogenous) nucleic acid encoding an AOAH polypeptide.
• the recombinant (i.e. exogenous) ANGPT1 polypeptide comprises or consists of a sequence that is at least 50, 60 or 70% identical to the amino acid sequence of mature native human ANGPT1 depicted in FIG. 9A/SEQ ID NO:7 (residues 16-498) and that exhibits the biological activity of native human ANGPT 1 , e.g., the ability to bind and activate the TEK/TIE2 receptor.
• the recombinant i.e. exogenous
• exogenous ANGPT1 polypeptide comprises or consists of a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of mature native human ANGPT1 depicted in FIG. 9A/SEQ ID NO:7 (residues 16-498) and that exhibits the biological activity of native human ANGPT1 .
• the recombinant (i.e. exogenous) ANGPT1 polypeptide comprises or consists of a sequence that is at least 70% identical to the amino acid sequence of full-length native human ANGPT1 depicted in FIG.
• the recombinant (i.e. exogenous) ANGPT1 polypeptide comprises or consists of a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of full-length native human ANGPT1 depicted in FIG. 9A/SEQ ID NO:7 (residues 1 -498) and that exhibits the biological activity of native human ANGPT 1 .
• the recombinant (i.e. exogenous) ANGPT1 polypeptide may be the native human ANGPT1 protein (full-length or mature form) or a biologically active variant thereof comprising amino acid deletions, substitutions and/or additions that do not significantly interfere with the biological activity.
• the variant exhibits a biological activity that is at least 70%, 75%, 80%, 85%, 90%, 95% or 100% that of native human ANGPT1 .
• the variant does not comprise a mutation in a region involved in ANGPT1 oligomerization, for example a mutation in the super clustering domain (residues 81 -1 19) or the central coiled domain (residues 153-261 ).
• the variant does not comprise a mutation in the fibrinogen C-terminal domain (residues 277-497). In further embodiments, the variant does not comprise a mutation of position 1 19 (e.g., A1 19S) and/or position 249 (e.g., K249R). In another embodiment, the variant does not comprise a deletion of the five C-terminal amino acids.
• the variant comprises one or more conservative substitutions, as defined above for AOAH.
• the non-conservative amino acid substitution enhances the biological activity of the variant, such that the biological activity of the variant is increased relative to the native ANGPT1 protein or polypeptide.
• the MSC is transformed by a recombinant nucleic acid encoding the recombinant (i.e. exogenous) ANGPT1 polypeptide.
• the present disclosure relates to a genetically-modified MSC comprising a recombinant (i.e. exogenous) nucleic acid encoding an ANGPT1 polypeptide.
• nucleic acid shall mean any nucleic acid molecule, including, without limitation, DNA, RNA and hybrids or modified variants thereof.
• An “exogenous” or“recombinant” nucleic acid relates to any nucleic acid introduced into the cell, which is not a component of the cells “original” or “natural” genome. Exogenous nucleic acids may be integrated or non- integrated, or relate to stably transfected nucleic acids.
• the recombinant nucleic acid may be a DNA or mRNA molecule comprising a nucleotide sequence encoding the recombinant (i.e. exogenous) AOAH polypeptide and/or the second polypeptide (e.g., ANGPT1).
• Methods for introducing recombinant nucleic acids into cell are well known in the art. Examples of such methods include, but are not limited to, the use of a lipid, protein, particle, or other molecule capable of facilitating cell transformation with the nucleic acid, electroporation.
• an MSC also can be contacted with a nucleic acid encoding AOAH and/or the second polypeptide (e.g., ANGPT1 ) in vivo, such as by way of a gene gun, for example.
• the recombinant nucleic acid encoding AOAH comprises a nucleotide sequence that is at least 70% identical to the nucleotide sequence encoding the full- length, precursor or mature form of human AOAH depicted in FIG. 8B/SEQ ID NO:6. In embodiments, the recombinant nucleic acid encoding AOAH comprises a nucleotide sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence encoding the full-length, precursor or mature form of human AOAH depicted in FIG. 8B/SEQ ID NO:6. In a further embodiment, the recombinant nucleic acid encoding AOAH comprises the nucleotide sequence encoding the full-length, precursor or mature form of human AOAH depicted in FIG. 8B/SEQ ID NO:6.
• the nucleic acid encoding AOAH comprises a codon-optimized nucleotide sequence encoding human AOAH.
• codon optimization of the nucleotide sequence increases the translation efficiency of the mRNA transcripts. Codon optimization of the nucleotide sequence may involve substituting a native codon for another codon that encodes the same amino acid, but can be translated by tRNA that is more readily available within a cell, thus increasing translation efficiency. Optimization of the nucleotide sequence may also reduce secondary mRNA structures that would interfere with translation, thus increasing translation efficiency.
• nucleic acid encoding AOAH may comprise the codon-optimized nucleotide sequence depicted in FIG. 6B/SEQ ID NO:1 (nucleotides 7-1734), or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% therewith.
• the recombinant nucleic acid encoding ANGPT1 comprises a nucleotide sequence that is at least 70% identical to the nucleotide sequence encoding the full- length, precursor or mature form of human ANGPT1 depicted in FIGs. 9B-9C/SEQ ID NO:8.
• the recombinant nucleic acid comprises a nucleotide sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence encoding the full-length, precursor or mature form of human ANGPT1 depicted in FIGs. 9B- 9C/SEQ ID NO:8.
• the nucleic acid encoding ANGPT1 comprises a codon-optimized nucleotide sequence encoding human ANGPT1 .
• the recombinant nucleic acid is present in a vector or plasmid, i.e. a recombinant expression vector or plasmid.
• the present disclosure relates to a genetically modified MSC comprising a recombinant expression vector comprising the nucleic acid encoding an AOAH polypeptide as described herein.
• the genetically modified MSC further comprises a recombinant expression vector comprising the nucleic acid encoding an ANGPT1 polypeptide as described herein.
• the nucleic acids encoding AOAH and ANGPT1 are present in different recombinant expression vectors.
• the nucleic acids encoding AOAH and ANGPT1 are present in the same recombinant expression vector.
• the recombinant expression vector or plasmid can be any suitable recombinant expression vector or plasmid that contains a recombinant nucleic acid as described above, Suitable vectors include those designed for expression of a gene of interest in MCSs, which are well known in the art.
• the recombinant expression vector or plasmid is a miniplasmid.
• Miniplasmids are small ( ⁇ 4kb) circular plasmid derivatives that have been freed from all prokaryotic vector parts (i.e. they contain no bacterial DNA sequences) that used as transgene carriers for the genetic modification of mammalian cells.
• Miniplasmids and uses thereof are described, for example, in Minicircle and Miniplasmid DNA Vectors: The Future of Nonviral and Viral Gene Transfer, by Dr. Martin Schleef (editor), May 2013, Wiley-Blackwell, 258 pages.
• the recombinant expression vector is a viral vector.
• Genetically modified viruses have been widely applied for the delivery of genes into stem cells including MSCs.
• Preferred viral vectors for genetic modification of the MSCs described herein relate to retroviral vectors, in particular to gamma retroviral vectors.
• the gamma retrovirus (sometimes referred to as mammalian type C retroviruses) is a sister genus to the lentivirus clade, and is a member of the Orthoretrovirinae subfamily of the retrovirus family.
• the Murine leukemia virus (MLV or MuLV), the Feline leukemia virus (FeLV), the Xenotropic murine leukemia virus-related virus (XMRV) and the Gibbon ape leukemia virus (GALV) are members of the gamma retrovirus genus.
• MMV or MuLV The Murine leukemia virus
• FeLV Feline leukemia virus
• XMRV Xenotropic murine leukemia virus-related virus
• GALV Gibbon ape leukemia virus
• the Murine Leukemia Virus a simple gammaretrovirus
• MMV Murine Leukemia Virus
• a simple gammaretrovirus can be converted into an efficient vehicle of genetic therapeutics in the context of creating gamma retrovirus-modified MSCs and expression of a therapeutic transgene from said MSCs after delivery to a subject.
• Genetically modified viruses have been widely applied for the delivery of genes into stem cells.
• Adenoviruses may be applied, or RNA viruses such as Lentiviruses, or other retroviruses.
• Adenoviruses have been used to generate a series of vectors for gene transfer cellular engineering. The initial generation of adenovirus vectors were produced by deleting the E1 gene (required for viral replication) generating a vector with a 4kb cloning capacity.
• Lentiviruses are members of Retroviridae family of viruses (M. Scherr et al., Curr Gene Ther. 2002 Feb; 2(1):45-55). Lentivirus vectors are generated by deletion of the entire viral sequence with the exception of the LTRs and cis acting packaging signals. The resultant vectors have a cloning capacity of about 8 kb.
• retroviral vectors One distinguishing feature of these vectors from retroviral vectors is their ability to transduce dividing and non-dividing cells as well as terminally differentiated cells.
• the recombinant expression vector or plasmid can comprise regulatory sequences, such as transcription and translation initiation and termination codons, which are specific to the type of host (e.g., an animal such as a human) into which the vector is to be introduced, as appropriate, and taking into consideration whether the vector is DNA- or RNA-based.
• the recombinant expression vector or plasmid can include one or more marker genes, which allow for selection of transformed or transfected hosts.
• Marker genes include biocide resistance, e.g., resistance to antibiotics, heavy metals, etc., complementation in an auxotrophic host to provide prototrophy, and the like
• Suitable marker genes for the recombinant expression vectors include, for instance, neomycin G418 resistance genes, hygromycin resistance genes, tetracycline resistance genes, and ampicillin resistance genes, and the like.
• the recombinant expression vector or plasmid can comprise a native or normative promoter operably linked to the nucleic acid encoding AOAH and/or the second polypeptide (e.g., ANGPT1), and that is functional in MSCs.
• the selection of a promoter is within the ordinary skill of the artisan.
• the combining of a nucleotide sequence with a promoter is also within the skill of the artisan.
• the promoter cars be a non-viral promoter or a viral promoter, e.g., a cytomegalovirus (CMV) promoter, an SV40 promoter, an RSV promoter, or a promoter found in the long-terminal repeat of the murine stem cell virus.
• CMV cytomegalovirus
• the promoter may comprise various motifs that enhance the binding of transcription factors such as initiator (INR), motif ten element (MTE) and downstream promoter element (DPE) motifs (see, e.g., Martinez, Transcription. 2012; 3(6): 295-299).
• the recombinant expression vector can be designed for either transient expression, for stable expression, or for both. Also, the recombinant expression vectors can be made for constitutive expression or for inducible expression.
• the vectors useful in the context of the disclosure can be "naked"' nucleic acid vectors (i.e., vectors having little or no proteins, sugars, and/or lipids encapsulating them), or vectors complexed with other molecules.
• Other molecules that can be suitably combined with the vectors include without limitation viral coats, cationic lipids, liposomes, polyamines, gold particles, and targeting moieties such as ligands, receptors, or antibodies that target cellular molecules.
• Any given gene delivery method is encompassed by the disclosure and preferably relates to viral or non-viral vectors as described above, as well as biological or chemical methods of transfection.
• the methods can yield either stable or transient gene expression in the system used.
• Non-viral methods include conventional plasmid transfer and the application of targeted gene integration through the use of genome editing technologies, as described above. These represent approaches for vector transformation that have the advantage of being both efficient, and often site-specific in their integration.
• Physical methods to introduce vectors into cells are known to a skilled person.
• One example relates to electroporation, which relies on the use of brief, high voltage electric pulses which create transient pores in the membrane by overcoming its capacitance.
• One advantage of this method is that it can be utilized for both stable and transient gene expression in most cell types.
• Alternative methods relate to the use of liposomes, protein transduction domains or other suitable reagents promoting nucleic acid entry in a cell. Appropriate methods are known to a skilled person and are
• MSCs Mesenchymal stem cells
• mesenchymal stromal cells are cells found in bone marrow, blood, dental pulp cells, adipose tissue, skin, spleen, pancreas, brain, kidney, liver, heart, retina, brain, hair follicles, intestine, lung, lymph node, thymus, bone, ligament, tendon, skeletal muscle, dermis, and periosteum.
• MSC Mesenchymal stem cells
• MSCs are capable of differentiating into a large number of cell types including, but not limited to, adipose, osseous, cartilaginous, elastic, muscular, and fibrous connective tissues.
• the specific lineage- commitment and differentiation pathway entered into by MSCs depends upon various influences, including mechanical influences and/or endogenous bioactive factors, such as growth factors, cytokines, and/or local microenvironmental conditions established by host tissues.
• MSCs are thus non-hematopoietic progenitor cells that divide to yield daughter cells that are either stem cells or are precursor cells that in time will irreversibly differentiate to yield a phenotypic cell. Examples of MSCs include mesenchymal precursor cells (MPCs).
• MPCs mesenchymal precursor cells
• MSCs are known to exhibit immune evasive properties after administration to a patient. MSCs have been shown to exhibit a beneficial immune modulatory effect in cases of transplantation of allogeneic donor material (Le Blanc et al., Lancet 2004: 363, p. 1439), thereby reducing a potentially pathogenic alloreactivity and rejection.
• the therapeutic delivery of MSCs can be performed via systemic injection, followed by MSC homing to and engraftment within sites of injury (Kidd et al., Stem Cells 2009: 27, p. 2614).
• the MSCs can be progeny cells (which can also be referred to as expanded cells).
• Progeny cells can be produced from the in vitro culture of stem cells. Expanded cells of the disclosure may have a wide variety of phenotypes depending on the culture conditions (including the number and/or type of stimulatory factors in the culture medium), the number of passages and the like.
• the progeny cells are obtained after about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 passages from the parental population.
• the progeny cells may be obtained after any number of passages from the parental population.
• the progeny cells can be obtained by culturing in a suitable culture medium.
• the progeny cells are multipotential expanded MSC progeny (MEMPs) as described in WO 2006/032092.
• MSCs multipotential expanded MSC progeny
• Methods for preparing enriched populations of MSC from which progeny may be derived are described in WO 01/04268 and WO 2004/085630.
• MSCs will rarely be present as an absolutely pure preparation and will generally be present with other cells that are tissue-specific committed cells (TSCCs).
• TSCCs tissue-specific committed cells
• WO 01 /04268 refers to harvesting such cells from bone marrow at purity levels of about 0.1 % to 90%.
• the population comprising MSC from which progeny are derived may be directly harvested from a tissue source, or alternatively it may be a population that has already been expanded ex vivo.
• the progeny may be obtained from a harvested, unexpanded, population of substantially purified MSC, comprising at least about 0.1 , 1 , 5, 10, 20, 30, 40, 50, 60, 70, 80 or 95% of total cells of the population in which they are present.
• This level may be achieved, for example, by selecting for cells that are positive for at least one marker typically expressed on MSCs such as CD29, CD44, CD90, CD49a-f, CD51 , CD73 (SH3), CD105 (SH2), CD106, CD166, and Stro-1 , and/or negative for markers such as CD45, CD34, CD14 or CD1 1 b, CD79a or CD19 and HLA-DR.
• markers such as CD45, CD34, CD14 or CD1 1 b, CD79a or CD19 and HLA-DR.
• the progeny may be obtained from a harvested, unexpanded, population of substantially purified MSC, comprising at least about 0.1 , 1 , 5, 10, 20, 30, 40, 50, 60, 70, 80 or 95% of total cells of the population in which they are present.
• This level may be achieved, for example, by selecting for cells that are positive for at least one marker selected from CD29, CD44, CD90, CD49a-f, CD51 , CD73 (SH3), CD105 (SH2), CD106, CD166, and Stro-1 .
• the MSC starting population may be derived from any one or more tissue types set out in WO 01/04268 or WO 2004/085630, namely bone marrow, dental pulp cells, adipose tissue and skin, or perhaps more broadly from adipose tissue, teeth, dental pulp, skin, liver, kidney, heart, retina, brain, hair follicles, intestine, lung, spleen, lymph node, thymus, pancreas, bone, ligament, bone marrow, tendon, and skeletal muscle.
• tissue types set out in WO 01/04268 or WO 2004/085630, namely bone marrow, dental pulp cells, adipose tissue and skin, or perhaps more broadly from adipose tissue, teeth, dental pulp, skin, liver, kidney, heart, retina, brain, hair follicles, intestine, lung, spleen, lymph node, thymus, pancreas, bone, ligament, bone marrow, tendon, and skeletal
• MEMPS can be distinguished from freshly harvested MSCs in that they are positive for the marker Stro-1 and negative for the marker Alkaline phosphatase (ALP). In contrast, freshly isolated MSCs are positive for both Stro-1 and ALP. In a preferred embodiment of the present disclosure, at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% of the administered cells have the phenotype Stro-1 + , ALP-.
• Reference to a cell "positive” (also "+") for a given marker means that it may be either a low (lo or dim) or a high (bright, bri) expresser of that marker depending on the degree to which the marker is present on the cell surface, where the terms relate to intensity of fluorescence or other color used in the color sorting process of the cells.
• lo or dim or dull
• bri will be understood in the context of the marker used on a particular cell population being sorted.
• Reference to a cell as being “negative” (or "-") for a given marker does not mean that the marker is not expressed at all by that cell. It means that the marker is expressed at a relatively very low level by that cell, and that it generates a very low signal when detectably labeled.
• the cells are taken from a patient with SIRS or sepsis, or a subject not suffering from SIRS or sepsis, genetically-modified to overexpress AOAH (and optionally a second polypeptide, such as ANGPT1 ), and optionally cultured in vitro using standard techniques, and administered to a patient in need of treatment as an autologous or allogeneic transplant.
• AOAH overexpress AOAH
• ANGPT1 optionally a second polypeptide, such as ANGPT1
• cells of one or more of the established human cell lines are used.
• cells of a non-human animal or if the patient is not a human, from another species are used.
• the present technology can be practiced using cells from any non-human animal species, including but not limited to non-human primate cells, ungulate, canine, feline, lagomorph, rodent, avian, and fish cells.
• Primate cells with which the disclosure may be performed include but are not limited to cells of chimpanzees, baboons, cynomolgus monkeys, and any other New or Old World monkeys.
• Ungulate cells with which the disclosure may be performed include but are not limited to cells of bovines, porcines, ovines, caprines, equines, buffalo and bison.
• Rodent cells with which the disclosure may be performed include but are not limited to mouse, rat, guinea pig, hamster and gerbil cells.
• Examples of lagomorph species with which the disclosure may be performed include domesticated rabbits, jack rabbits, hares, cottontails, snowshoe rabbits, and pikas.
• Chickens ( Gallus gattus) are an example of an avian species with which the disclosure may be performed.
• MSCs can be stored before use.
• Methods and protocols for preserving and storing of eukaryotic cells, and in particular mammalian cells, are well known in the art (see, for example, Pollard, J. W. and Walker, J. M. (1997) Basic Cell Culture Protocols, Second Edition, Humana Press, Totowa, N.J.; Freshney, R. I. (2000) Culture of Animal Cells, Fourth Edition, Wiley-Liss, Hoboken, N.J.).
• Any method maintaining the biological activity of the isolated stem cells such as mesenchymal stem/progenitor cells, or progeny thereof, may be utilized in connection with the present disclosure.
• the cells are maintained and stored by using cryo-preservation.
• MSCs can be obtained using a variety of techniques. For example, a number of cellsorting techniques by which cells are physically separated by reference to a property associated with the cell-antibody complex, or a label attached to the antibody can be used. This label may be a magnetic particle or a fluorescent molecule.
• the antibodies may be cross-linked such that they form aggregates of multiple cells, which are separable by their density. Alternatively, the antibodies may be attached to a stationary matrix, to which the desired cells adhere.
• a “culture medium” as used herein, encompasses (a) both a culture medium that contains the typical components used for culturing a MSC, such as amino acids, glucose, and various salts, with or without the MSC, and (b) a composition isolated from the culture medium, including a composition comprising components released from the MSC during the culturing.
• the culture medium may contain components that are solid, liquid, gaseous or a mixture of phases and materials.
• Culture medium components include, but are not limited to, agar, agarose, gelatin and collagen matrices.
• “Culture medium” includes material that is intended for use in a cell culture, even if it has not yet been contacted with cells. For example, a nutrient rich liquid prepared for bacterial culture can be a culture medium.
• the MSCs are contacted with or exposed to one or more agents during or after culture/expansion (and prior to administration/use in the subject) to confer them with a desired property, e.g. to induce the expression/secretion of anti-inflammatory mediators and/or to inhibit the expression/secretion of pro-inflammatory mediators.
• MSCs exposed to low concentration prostacyclins e.g., treprostinil
• treprostinil for example about 10 pg/mL of treprostinil
• Such exposure to the one or more agents may be for any suitable time to induce the desired effect, for example at least 6, 12, 18, 24, 36 or 48 hours.
• the present disclosure relates to the genetically-modified MSC described herein, or a pharmaceutical composition comprising same, for use as a medicament.
• the medicament is for the prevention or treatment of SIRS, for example SIRS caused by sepsis, in a subject.
• SIRS systemic inflammatory response syndrome
• the present disclosure also relates to a method for preventing or treating systemic inflammatory response syndrome (SIRS) comprising administering to a subject in need thereof an effective amount of the genetically-modified MSC described herein, or a pharmaceutical composition comprising same.
• SIRS systemic inflammatory response syndrome
• the present disclosure also relates to the use of the genetically-modified MSC described herein, or a pharmaceutical composition comprising same, for preventing or treating SIRS in a subject.
• the present disclosure also relates to the use of the genetically-modified MSC described herein, or a pharmaceutical composition comprising same, for the manufacture of a medicament for preventing or treating SIRS in a subject.
• the terms "treating”, “treat” or “treatment” include eliminating, ameliorating, alleviating, or abating a disease or condition or one or more symptoms thereof, whether or not the disease or condition is considered to be “cured” or “healed” and whether or not all symptoms are resolved.
• the terms also include reducing or preventing progression of a disease or condition or one or more symptoms thereof, impeding or preventing an underlying mechanism of a disease or condition or one or more symptoms thereof, and achieving any therapeutic and/or prophylactic benefit.
• preventing include reducing the occurrence and/or severity of a disease or condition or one or more symptoms thereof in a subject (e.g., a subject at risk of suffering from SIRS/sepsis) relative to an untreated control subject, or delaying the onset of one or more symptoms of the disease or condition in a subject (e.g., a subject at risk of suffering from SIRS/sepsis) relative to the untreated control subject.
• SIRS systemic inflammatory response syndrome
• ALI acute lung injury
• the SIRS is associated or caused by sepsis.
• the term "sepsis” is applied to a number of diseases, conditions and/or syndromes which may have an infectious (for example viral, bacterial and/or fungal) etiology. It encompasses sepsis (which is often defined as "SIRS in response to an infectious process"), severe sepsis (that is sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion (which itself might manifest as hypotension, elevated lactate or decreased urine output) and septic shock (severe sepsis plus persistently low blood pressure despite, for example, the administration of intravenous fluids).
• Bacterial sepsis is most often applied to diseases, conditions and/or syndromes which result from “bacterial sepsis”. Bacterial sepsis may stem from the presence of bacteria in blood and may sometimes be referred to as “bacteremia” or “septicemia”. The term “sepsis” may also embrace diseases and/or conditions which are caused or contributed to by the presence of bacterial components such as LPS, toxins and/or membrane fragments in the blood. Components of this type may originate from primary infections present in other tissues and/or organs, for example, infections present in the lungs, brain, skin, urinary tract, pelvis and/or abdomen. Sepsis can be a very severe condition which occasionally leads to multiple organ failure and death.
• sepsis associated pathologies There may be a number of pathologies and/or symptoms associated with each type of sepsis and these will be collectively referred to hereinafter as "sepsis associated pathologies".
• sepsis associated pathologies may include, for example, fever, increased heart rate, increased rate of respiration and/or low blood pressure.
• the primary mechanism which underpins the pathology of sepsis and many of the symptoms and outcomes associated therewith is an exacerbated, exaggerated and/or inappropriate host immune response. This exacerbated immune response (which is the body's response to infection) leads to host tissue damage and/or organ damage/failure.
• the exacerbated or inappropriate immune response may include the dysregulation of innate immune responses as well as the production and/or over production of certain pro-coagulation cytokines (including, for example, tumor necrosis factor, interleukin-1 (IL-1) and interleukin-6 (IL-6)).
• pro-coagulation cytokines including, for example, tumor necrosis factor, interleukin-1 (IL-1) and interleukin-6 (IL-6).
• the treatment reduces one or more symptoms of SIRS or sepsis.
• the treatment reduces the levels (e.g., plasmatic levels) of one or more pro- inflammatory cytokines such as IL-6, IL-10, IL-12, MIP-1 a (CCL3), eotaxin, G-CSF, KC and/or MCP-1 , in the subject.
• the treatment reduces the levels (e.g., plasmatic levels) of at least one of IL-10, MIP-l a, and MCP-1 , and preferably the treatment reduces the levels (e.g., plasmatic levels) of IL-10, MIP-l a, and MCP-1.
• the term "subject” includes warm-blooded animals, preferably mammals, including humans.
• the subject is a primate.
• the subject is a human.
• the subject has one or more symptoms of SIRS or sepsis.
• the subject is at risk of developing SIRS or sepsis.
• the genetically-engineered MSCs described herein are present in a composition, preferably a pharmaceutical composition.
• a pharmaceutical composition comprising the genetically-engineered MSCs described herein.
• the pharmaceutical composition comprises a therapeutically effective amount of the genetically-engineered MSCs described herein.
• the pharmaceutical composition further comprises at least one pharmaceutically-acceptable carrier or excipient.
• pharmaceutically-acceptable carrier or excipient refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• pharmaceutically-acceptable carrier or excipient as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material.
• Pharmaceutically acceptable carriers or excipients include saline, aqueous buffer solutions, solvents and/or dispersion media.
• the use of such carriers or excipients are well known in the art.
• the solution is preferably sterile and fluid to the extent that easy syringability exists.
• the solution is stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi through the use of preservatives, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
• materials and solutions which can serve as pharmaceutically- acceptable carriers or excipients include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; lubricants such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic cellulose,
• compositions useful for the methods of the disclosure may comprise a polymeric carrier or extracellular matrix.
• a polymeric carrier or extracellular matrix A variety of biological or synthetic solid matrix materials (e.g., solid support matrices, biological adhesives or dressings, and biological/medical scaffolds) are suitable for use in this disclosure.
• the matrix material is preferably medically acceptable for use in in vivo applications.
• Non-limiting examples of such medically acceptable and/or biologically or physiologically acceptable or compatible materials include, but are not limited to, solid matrix materials that are absorbable and/or non-absorbable, such as small intestine submucosa (SIS), e.g., porcine-derived (and other SIS sources); crosslinked or non-crosslinked alginate, hydrocolloid, foams, collagen gel, collagen sponge, polyglycolic acid (PGA) mesh, polyglactin (PGL) mesh, fleeces, foam dressing, bioadhesives (e.g., fibrin glue and fibrin gel) and dead de-epidermized skin equivalents in one or more layers.
• SIS small intestine submucosa
• PGA polyglycolic acid
• PGL polyglactin
• Suitable polymeric carriers include porous meshes or sponges formed of synthetic or natural polymers, as well as polymer solutions.
• One form of matrix is a polymeric mesh or sponge; the other is a polymeric hydrogel.
• Natural polymers that can be used include proteins such as collagen, albumin, and fibrin; and polysaccharides such as alginate and polymers of hyaluronic acid.
• Synthetic polymers include both biodegradable and non-biodegradable polymers. Examples of biodegradable polymers include polymers of hydroxy acids such as polylactic acid (PLA), polyglycolic acid (PGA), and polylactic acid-glycolic acid (PLGA), polyorthoesters, polyanhydrides, polyphosphazenes, and combinations thereof.
• Nonbiodegradable polymers include polyacrylates, polymethacrylates, ethylene vinyl acetate, and polyvinyl alcohols.
• a hydrogel is a substance formed when an organic polymer (natural or synthetic) is cross-linked via covalent, ionic, or hydrogen bonds to create a three- dimensional open-lattice structure which entraps water molecules to form a gel.
• Examples of materials which can be used to form a hydrogel include polysaccharides such as alginate, polyphosphazines, and polyacrylates, which are crosslinked ionically, or block copolymers such as PluronicsTM or TetronicsTM, polyethylene oxide-polypropylene glycol block copolymers which are crosslinked by temperature or pH, respectively.
• Other materials include proteins such as fibrin, polymers such as polyvinylpyrrolidone, hyaluronic acid and collagen.
• these polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a monovalent ionic salt thereof.
• aqueous solutions such as water, buffered salt solutions, or aqueous alcohol solutions
• polymers with acidic side groups that can be reacted with cations are poly(phosphazenes), poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, poly(vinyl acetate), and sulfonated polymers, such as sulfonated polystyrene.
• Copolymers having acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used.
• Examples of acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and acidic OH groups.
• Examples of polymers with basic side groups that can be reacted with anions are poly(vinyl amines), poly(vinyl pyridine), poly(vinyl imidazole), and some imino substituted polyphosphazenes.
• the ammonium or quaternary salt of the polymers can also be formed from the backbone nitrogens or pendant imino groups.
• Examples of basic side groups are amino and imino groups.
• the pharmaceutical composition can comprise at least one additional therapeutic agent.
• the composition may contain an analgesic to aid in treating inflammation or pain, or an anti-infective agent to prevent infection of the site treated with the composition.
• useful therapeutic agents include the following therapeutic categories: analgesics, such as nonsteroidal antiinflammatory drugs, opiate agonists and salicylates; anti-infective agents, such as antihelmintics, antianaerobics, antibiotics, aminoglycoside antibiotics, antifungal antibiotics, cephalosporin antibiotics, macrolide antibiotics, miscellaneous b-lactam antibiotics, penicillin antibiotics, quinolone antibiotics, sulfonamide antibiotics, tetracycline antibiotics, antimycobacterials, antituberculosis antimycobacterials, antiprotozoals, antimalarial antiprotozoals, antiviral agents, anti-retroviral agents, scabicides, anti-inflammatory agents,
• analgesics such as nonster
• the compositions can be co administered with at least one other medicine for SIRS or sepsis.
• the pharmaceutical compositions can be co-administered with antibiotics, intravenous fluid, corticosteroids, insulin, pain killers, sedatives, and/or vasopressors, for example.
• the combination of prophylactic/therapeutic agents and/or compositions of the present disclosure may be administered or co-administered (e.g., consecutively, simultaneously, at different times) in any conventional dosage form.
• Co-administration in the context of the present disclosure refers to the administration of more than one therapeutic in the course of a coordinated treatment to achieve an improved clinical outcome.
• Such co-administration may also be coextensive, that is, occurring during overlapping periods of time.
• a first agent may be administered to a patient before, concomitantly, before and after, or after a second active agent is administered.
• the agents may in an embodiment be combined/formulated in a single composition and thus administered at the same time.
• compositions useful for the methods of the present disclosure may include cell culture components, e.g., culture media including amino acids, metals, coenzyme factors, as well as small populations of other cells, e.g., some of which may arise by subsequent differentiation of the stem cells.
• cell culture components e.g., culture media including amino acids, metals, coenzyme factors, as well as small populations of other cells, e.g., some of which may arise by subsequent differentiation of the stem cells.
• compositions useful for the methods of the present disclosure may be prepared, for example, by sedimenting out the subject cells from the culture medium and re-suspending them in the desired solution or material.
• the cells may be sedimented and/or changed out of the culture medium, for example, by centrifugation, filtration, ultrafiltration, etc.
• the skilled artisan can readily determine the amount of MSCs and optional carrier(s) in compositions and to be administered in methods of the disclosure.
• toxicity such as by determining the lethal dose (LD) and LD 5 o in a suitable animal model e.g., rodent such as mouse; and, the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit a suitable response.
• LD lethal dose
• LD 5 o a suitable animal model e.g., rodent such as mouse
• the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit a suitable response Such determinations do not require undue experimentation from the knowledge of the skilled artisan, this disclosure and the documents cited herein. And, the time for sequential administrations can be ascertained without undue experimentation.
• the following amounts and ranges of amounts of MSCs are administered to the subject: (i) from about 1 x 10 2 to about 1 x 10 8 cells/kg body weight; (ii) from about 1 x 10 3 to about 1 x 10 7 cells/kg body weight; (iii) from about 1 x 10 4 to about 1 x
• the MSCs may be administered either in a bolus form, i.e. injection of all the cells during a short period of time, or it may be accomplished by a continuous administration (e.g., infusion) of small numbers of cells over a long period of time, or alternatively by administration of limited size boluses on several occasions over a period of time.
• compositions useful for the methods of the present disclosure can be administered via, inter alia, localized injection, including catheter administration, systemic injection, localized injection, intravenous injection, intrauterine injection or parenteral administration.
• a therapeutic composition described herein e.g., a pharmaceutical composition
• it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion).
• Example 1 Construction of plasmids for expression of AOAH in MSC
• AOAH gene was synthesized by GenScript, Restriction endonuclease Nhel, Sail, BamHI, and EcoRI were purchased from New England Biolabs, T4 DNA Ligase was purchased from New England Biolabs.
• AOAH gene was synthesized, gene sequence was checked by gene sequencing. Then the target gene was cut by restriction endonucleases at 37°C for 2h, and inserted into parental cloning vector by using T4 DNA Ligase and incubating at 16°C overnight. The parental AOAH plasmid was transformed into competent E. coli for amplification and miniplasmid preparation.
• plasmid #1 Three different plasmids were constructed and tested for expression of AOAH in MSC, namely a plasmid comprising the AOAH coding sequence under the control of an EF-1 promoter (plasmid #2, FIG. 1A), a plasmid comprising the AOAH coding sequence under the control of an CMV promoter (plasmid #3, FIG. 1 B), and another plasmid comprising the AOAH coding sequence under the control of a CMV promoter/enhancer (plasmid #1 , FIG. 1C).
• MCS were transfected with the different plasmids and the intracellular expression level of AOAH were measured on cell lysates by Western Blot. The results depicted in FIG.
• Anti-AOAH antibody was purchased from ThermoFisher, anti-AOAH ELISA kit was purchased from MyBioSource.
• MSC were seeded at the density of 10,000/cm 2 into T75 flask. 16 ⁇ 20 h post- seeding, cells were transfected with plasmid #1 ( ⁇ 1 pg/100,000 cells). After transfection, cells were cultured for 24h. 40 pg of cell lysates was used for Western Blot. Culture medium was harvested and assayed by ELISA.
• plasmid #1 was transfected into MSC, and Western Blots were performed on the cell lysates harvested at 24h, 48h, and 72h post-transfection. It was found that the total level of intracellular AOAH (precursor and mature form) was slightly lower at 72h relative to 24h post-transfection (FIG. 3A). However, the proportion of the mature form of AOAH (relative to total AOAH) was higher at 72h relative to 24h post-transfection ( ⁇ 45% vs ⁇ 24%, FIG. 3B). Thus, the transfection of MSC with plasmid #1 leads to a sustained expression of mature AOAH in these cells. The results presented in FIG. 3C show a gradual increase from 24h to 72h in the levels of AOAH in the culture medium of MSC transfected with plasmid #1 .
• Example 3 Effect of administration of MSC transfected with the plasmid #1 encoding
• coli was diluted with sterilized saline solution, and injected intraperitoneally into mice at a dose of 1 .2x10 ® CFU per mouse.
• 1 h post- IP injection cells were delivered by intrajugular injection at a dose of 250,000 cells per mouse.
• 20h post-LPS injection 500 pi of blood from each mouse was drawn by a syringe which was prefilled with 50 pi of 50 mM EDTA. The needle was removed from the syringe, and the blood was gently expelled into a microfuge tube. The blood was centrifuged at 1700 x g, 10 min at 4°C.
• the upper plasma layer was transferred to a new microfuge tube, and centrifuged at 1 1 ,000xg, 5 min at 4°C to remove any residual contaminating debris/platelets.
• the plasma was transferred to a new microfuge tube after centrifuge, and frozen at -80°C to preserve or determine cytokine levels. Cytokine levels were determined by Bio-Plex according to the manufacturer’s protocols.
• FIG. 5A In pathogenic E. coli-induced sepsis study, animals were observed for 5 days postbacteria inoculation to determine the survival rate (FIG. 5A). The results shown in FIG. 5B demonstrate that the administration of NT002 protects the mice from a high mortality ( ⁇ 50%) induced by the pathogenic E. coli inoculation.
• Example 4 Effect of administration of MSC overexpressing AOAH and ANGPT1 in murine models of sepsis
• MSCs were transfected with plasmid #4 (FIG. 6A) that comprises a codon-optimized sequence encoding hAOAH (FIG. 6B) and a sequence encoding hANGPTI (FIG. 6C) to induce overexpression of AOAH and ANGPT1 .
• plasmid #4 FIG. 6A
• NT003 The effects of these MSCs overexpressing AOAH and ANGPT1 (NT003) was assessed in the pathogenic E. coli- induced model of sepsis described above, as well as in the cecal ligation and puncture (CLP)-induced sepsis model (FIG. 7A). Mice were treated with NT003 or vehicle 6h post-CLP, and survival was measured 5 days post-CLP. The results shown in FIG.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Wood Science & Technology (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Developmental Biology & Embryology (AREA)
• Cell Biology (AREA)
• Microbiology (AREA)
• Molecular Biology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Biophysics (AREA)
• Hematology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Rheumatology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Vascular Medicine (AREA)
• Toxicology (AREA)
• Gastroenterology & Hepatology (AREA)
• Epidemiology (AREA)
• Virology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Physics & Mathematics (AREA)
• Plant Pathology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=70462996

Family Applications (1)

Country Status (10)

Cited By (1)

Families Citing this family (1)

Family Cites Families (15)

• 2019
  • 2019-10-29 EP EP19878837.4A patent/EP3874029B1/en active Active
  • 2019-10-29 ES ES19878837T patent/ES2962812T3/es active Active
  • 2019-10-29 US US17/289,311 patent/US20220010281A1/en not_active Abandoned
  • 2019-10-29 WO PCT/CA2019/051526 patent/WO2020087160A1/en not_active Ceased
  • 2019-10-29 JP JP2021547607A patent/JP7372982B2/ja active Active
  • 2019-10-29 AU AU2019370629A patent/AU2019370629A1/en not_active Abandoned
  • 2019-10-29 SG SG11202103509RA patent/SG11202103509RA/en unknown
  • 2019-10-29 KR KR1020217015632A patent/KR20210086662A/ko not_active Ceased
  • 2019-10-29 CN CN201980071846.5A patent/CN113166729A/zh active Pending
• 2021
  • 2021-04-29 IL IL282820A patent/IL282820A/en unknown

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events